. 2021 Apr 27;13(1):1914885. doi: 10.1080/19420862.2021.1914885

Table 2.

Binding affinity and kinetics parameter of trastuzumab and trastuzumab-MMAF conjugates against HER2

Sample	1^st measurement			2^nd measurement			Avg. K_D (nM)
Sample	k_a (M^-1s^-1)	k_d (s⁻¹)	K_D (nM)	k_a (M^-1s^-1)	k_d (s⁻¹)	K_D (nM)	Avg. K_D (nM)
Trastuzumab	3.46 E + 05	4.32 E-05	0.13	1.71 E + 05	3.75 E-05	0.22	0.18
T-N-F(DAR 1.6)	2.96 E + 05	3.51 E-05	0.12	9.55 E + 04	8.17 E-06	0.09	0.11
T-N-F(DAR 3.2)	3.81 E + 05	3.99 E-05	0.11	9.44 E + 04	6.23 E-06	0.07	0.09
T-C-F (DAR 3.7)	4.10 E + 05	3.74 E-05	0.09	1.14 E + 05	1.62 E-05	0.14	0.12
T-K-F (DAR 3.9)	5.31 E + 05	6.32 E-05	0.12	9.39E+04	2.03E-05	0.22	0.17

MMAF: monomethyl auristatin F, HER2: human epidermal growth factor receptor 2, DAR: drug-to-antibody ratio, T-N-F: trastuzumab-MMAF conjugate synthesized via NTERM conjugation, T-C-F: trastuzumab-MMAF conjugate synthesized via thiol conjugation, T-K-F: trastuzumab-MMAF conjugate synthesized via lysine conjugation.